登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第二十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份的议案》，同意公司使用自有资金以集中竞价 交易方式回购公司股份。本次回购的股份将在未来适宜时机用于员工持股计划或股权激励。回购资金总 金额不低于人民币1,500万元（含）且不超过人民币3,000万元（含），回购股份价格不超过人民币25.32 元/股（含），回购股份期限为自公司董事会审议通过回购方案之日起不超过12个月。 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引第 7 号一一回购股份》等相 关规定，现将公司截至上月末回购股份的进展情况公告如下： 截至2026年1月31日，公司通过上海证券交易所系统以集中竞价交易方式已回购公司股份272,799股，占 目前公司总股本140,364,345股的比例为0.19%，回购成交 ...

■ 特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第二十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份的议案》，具体情况详见公司于2025年12月31 日披露于上海证券交易所网站（www.sse.com.cn）的《关于以集中竞价交易方式回购股份方案的公告暨 回购报告书》（公告编号：2025-072）。根据《上海证券交易所上市公司自律监管指引第7号一一回购 股份》等相关规定，现将公司披露第四届董事会第二十六次会议公告回购股份决议的前一个交易日（即 2025年12月30日）登记在册的前10大股东和前10大无限售条件股东的名称及持股数量、比例情况公告如 下： 一、公司前十大股东持股情况 ■ 二、公司前十大无限售条件股东持股情况 广州洁特生物过滤股份有限公司董事会 2026年1月8日 ...

Core Viewpoint - The company is potentially triggering a downward adjustment of the conversion price for its convertible bonds due to stock prices falling below a specified threshold, which may impact investor decisions and the company's financial strategy [2][8]. Convertible Bond Issuance - The company issued a total of 4.4 million convertible bonds with a face value of 100 RMB each, raising a total of 440 million RMB, with a maturity period from June 28, 2022, to June 27, 2028 [2][3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and will further adjust to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025, due to annual equity distribution plans [3][4]. Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5][6]. - The potential trigger for this adjustment is set to begin on November 3, 2025, with a threshold price of 40.76 RMB per share [8]. Adjustment Procedure - If the company decides to adjust the conversion price, it will announce the details, including the adjustment range and the record date for shareholders, through the Shanghai Stock Exchange [7].

Core Insights - Jiet Bio's stock increased by 5.45% to 19.14 CNY per share, with a trading volume of 36.47 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 2.687 billion CNY [1] Company Overview - Guangzhou Jiet Biofilter Co., Ltd. is located in the Yonghe Economic Zone of Guangzhou, Guangdong Province, established on April 11, 2001, and listed on January 22, 2020 [1] - The company's main business involves the research, development, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling [1] - Revenue composition: Liquid handling accounts for 60.24%, cell culture for 30.74%, other supplementary products for 4.98%, and instruments and other categories for 4.04% [1] Shareholder Information - Among the top ten circulating shareholders of Jiet Bio, one fund from Huaxia Fund, Huaxia CSI 500 Index Enhanced A (007994), has entered the list, holding 1.1212 million shares, which is 0.8% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.11 million CNY [2] - Huaxia CSI 500 Index Enhanced A was established on March 25, 2020, with a latest scale of 3.135 billion CNY, and has achieved a year-to-date return of 22.68% [2] Fund Manager Performance - The fund manager of Huaxia CSI 500 Index Enhanced A is Sun Meng, who has been in the position for 5 years and 220 days [3] - The total asset scale of the fund is 10.461 billion CNY, with the best return during the tenure being 126.46% and the worst return being 17.83% [3]

Core Insights - The company, Guangzhou Jiete Biological Filtration Co., Ltd., reported a revenue of 268 million yuan for the first half of 2025, representing a year-on-year growth of 13.50% [1] - The net profit attributable to shareholders reached 46.34 million yuan, marking a significant increase of 54.46% compared to the same period last year [1] - The growth in revenue was influenced by customers' anticipation of factory relocation and efforts to avoid Sino-U.S. trade frictions, leading to early inventory stocking [1] Group 1 - The company has actively pursued cost reduction and efficiency improvement by enhancing production automation and implementing cost management systems, resulting in better control over costs and increased price competitiveness of its products [1] - The company aims to provide comprehensive solutions for biological laboratories, with its main products including biological culture and liquid handling consumables, along with a range of related products and services [1] Group 2 - In line with the trends in the domestic life sciences and IVD industries, the company has increased its R&D investment in disposable plastic consumables for biological laboratories, focusing on market demands in cell therapy, biomedicine, and vaccine development [2] - The company has developed new products including reagent bottles, closed systems for shaking flasks, petri dishes, and centrifuge tube racks, and has filed 23 patent applications, with 15 patents granted during the reporting period [2] Group 3 - The company has established large-scale production bases in Guangzhou Huangpu and Zengcheng, featuring 65,000 square meters of GMP-grade clean production facilities [3] - With the full operation of the Zengcheng factory and the introduction of smart manufacturing workshops in 2025, the company's production capacity has significantly increased, making it one of the largest manufacturers in the domestic industry [3] - The company leverages its substantial production capacity to effectively control production costs and enhance product price competitiveness, while also establishing long-term stable partnerships with key international clients [3]

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is implementing a differentiated dividend distribution plan for the year 2024, which is based on the number of shares available after accounting for shares repurchased and held in a special account [1][2][5]. Group 1: Reasons for Differentiated Dividend - The differentiated dividend is a result of the company's decision to repurchase shares using its own or raised funds, with a total repurchase amount between RMB 20 million and RMB 40 million, and a maximum repurchase price of RMB 19.36 per share [1][2]. - The repurchased shares will not participate in profit distribution, leading to the need for a differentiated dividend distribution plan [2][3]. Group 2: Dividend Distribution Plan - The company plans to distribute a cash dividend of RMB 0.73 per 10 shares (including tax) to all shareholders based on the total share capital minus the repurchased shares [2][3]. - The actual number of shares participating in the distribution is 137,632,306 shares, calculated from the total share capital of 140,363,220 shares after deducting the repurchased shares [3][4]. Group 3: Calculation Basis for Differentiated Dividend - The cash dividend per share is calculated based on the adjusted total share capital, and the reference price for ex-dividend trading is determined using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [3][4]. - The impact of the differentiated dividend on the ex-dividend reference price is minimal, with an absolute value change of less than 1% [4]. Group 4: Verification Opinion - The sponsoring institution, Minsheng Securities, confirms that the differentiated dividend distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and all shareholders [5][6].

Group 1 - The company announced that the funds amounting to 11,473,149.78 yuan in its bank account have been unfrozen [1][2] - The funds were previously frozen due to a lawsuit filed by Shenzhen Hesheng Medical Technology Co., Ltd. regarding a mold procurement contract dispute [1] - The company has applied to the court to replace the frozen funds with other bank time deposits to minimize the impact of the lawsuit [1] Group 2 - Following the unfreezing, the company's bank account no longer has any frozen funds [2] - The lawsuit regarding the mold procurement contract is still under review by the Huangpu District People's Court and has not yet concluded [1]